About Tubulinyl-Tyr carboxypeptidase 2
Tubulinyl-Tyr carboxypeptidase 2 (VASH2) is a protein
from Homo sapiens identified by UniProt accession
Q86V25, 355 residues long.
MolForge cross-references it against 0 known binders and
85 disease associations.
Target properties
| Protein name | Tubulinyl-Tyr carboxypeptidase 2 |
|---|
| UniProt accession | Q86V25 |
|---|
| Gene | VASH2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 355 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (85)
Diseases linked to this target (Open Targets).
- grip strength measurement · score 0.34
- self reported educational attainment · score 0.28
- neutrophil count · score 0.26
- lymphocyte count · score 0.25
- lymphocyte percentage of leukocytes · score 0.19
- neoplasm · score 0.11
- mathematical ability · score 0.10
- reticulocyte count · score 0.10
- reticulocyte measurement · score 0.08
- non-small cell lung carcinoma · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q86V25-F1 | alphafold | PREDICTED | 80.45 | — |
Amino-acid sequence (355 residues)
MTGSAADTHR CPHPKGAKGT RSRSSHARPV SLATSGGSEE EDKDGGVLFH VNKSGFPIDS HTWERMWMHV AKVHPKGGEM VGAIRNAAFL AKPSIPQVPN YRLSMTIPDW LQAIQNYMKT LQYNHTGTQF FEIRKMRPLS GLMETAKEMT RESLPIKCLE AVILGIYLTN GQPSIERFPI SFKTYFSGNY FHHVVLGIYC NGRYGSLGMS RRAELMDKPL TFRTLSDLIF DFEDSYKKYL HTVKKVKIGL YVPHEPHSFQ PIEWKQLVLN VSKMLRADIR KELEKYARDM RMKILKPASA HSPTQVRSRG KSLSPRRRQA SPPRRLGRRE KSPALPEKKV ADLSTLNEVG YQIRI
Explore Tubulinyl-Tyr carboxypeptidase 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets